A set for peripheral nerve blocking, including a rigid cannula, an outer catheter sleeve which can be slid over the cannula, where the distal tip of the cannula protrudes over the distal end of the catheter sleeve, an inner catheter which can be inserted through the catheter sleeve after removal of the cannula from the catheter sleeve and which has an outlet opening at the distal end, and a first connector piece at the proximal end of the catheter sleeve, where the inner catheter has a second connector piece complementary to the first connector piece, and the inner catheter can be fixed in an axial position by connecting the first connector piece and the second connector piece in the catheter sleeve, in which axial position the distal end of the inner catheter protrudes from the distal end of the catheter sleeve with a pre-defined length which has the outlet opening.

In one embodiment, a system for locating a tip of a catheter that has been inserted into a patient includes an implantable catheter having a distal tip, a pulsed light source that is co-located with the distal tip of the implantable catheter, the pulsed light source being configured to emit pulses of light into surrounding patient tissue, an optoacoustic sensor configured to be applied so a skin surface of the patient at a position proximate to the pulsed light source and to sense optoacoustic waves generated when the pulses of light are absorbed by the surrounding patient tissue, and an optoacoustic console configured to receive optoacoustic wave signals from the optoacoustic sensor and to display an indication of the optoacoustic wave signals to a medical professional to provide an indication of the location of the pulsed light source and, therefore, the distal tip of the implantable catheter.

The disclosed systems and methods are configurable central nervous system (CNS) delivery solutions for therapeutics, such as genetic medicines. The systems and methods first infuse a therapeutic bolus within intrathecal space and subsequently infuse a flush fluid to move the therapeutic bolus rostrally toward a target area and achieve a desired spread in the spine and/or brain. The second location can be at a location caudal to the delivery location of the therapeutic bolus.

The disclosed systems and methods are configurable central nervous system (CNS) delivery solutions for therapeutics, such as genetic medicines. The systems and methods first infuse a therapeutic bolus within intrathecal space and subsequently infuse a flush fluid to move the therapeutic bolus rostrally toward a target area and achieve a desired spread in the spine and/or brain. The second location can be at a location caudal to the delivery location of the therapeutic bolus.

Systems and methods to assist a practitioner to confirm location of a distal tip of a needle within a patient include confirming tactile feedback from a needle insertion to a point of loss of resistance of fluid flow and by viewing a display showing color of a tissue plane at the distal tip of the needle at the point of loss of resistance.

A counter device for use in tracking an elongated medical device. The counter device includes a housing assembly and a tracking and display unit. The housing assembly defines an entrance opening, an exit opening, and a passageway. The passageway is open to and extends between the entrance and exit openings. The tracking and display unit is carried by the housing assembly and is configured to selectively interface with an elongated medical device disposed along the passageway. In a tracking state, the tracking and display unit generates information indicative of a distance of travel of the elongated medical device traveling along the passageway. In some embodiments, the tracking and display unit includes an engagement assembly rotatably coupled to the housing assembly. The engagement assembly can have a toothed engagement face.

The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.

Endovascular drug delivery systems and methods are disclosed herein for delivering a therapeutic agent to the intracranial subarachnoid space of a patient, and/or deploying an endovascular drug delivery device distal portion in the intracranial subarachnoid space and a portion of the drug delivery device body in a dural venous sinus such that a therapeutic agent is delivered from the deployed drug delivery device into the intracranial subarachnoid space.

The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.

Endovascular drug delivery systems and methods are disclosed herein for delivering a therapeutic agent to the intracranial subarachnoid space of a patient, and/or deploying an endovascular drug delivery device distal portion in the intracranial subarachnoid space and a portion of the drug delivery device body in a dural venous sinus such that a therapeutic agent is delivered from the deployed drug delivery device into the intracranial subarachnoid space.